Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
15512 | 638 | 33.2 | 86% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
669 | 12548 | PSORIASIS//PSORIATIC ARTHRITIS//CALCIPOTRIOL |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | DRUG INDUCED LUPUS | Author keyword | 4 | 21% | 3% | 18 |
2 | DRUG INDUCED LUPUS ERYTHEMATOSUS | Author keyword | 3 | 37% | 1% | 7 |
3 | TNF ALPHA ANTAGONISTS | Author keyword | 2 | 15% | 2% | 15 |
4 | ANTIBODIES MONOCLONAL ADVERSE EFFECTS | Author keyword | 2 | 67% | 0% | 2 |
5 | DRUG INDUCED PSORIASIS | Author keyword | 2 | 67% | 0% | 2 |
6 | LUPUS LIKE REACTION | Author keyword | 2 | 67% | 0% | 2 |
7 | LUPUS SYNDROME | Author keyword | 2 | 67% | 0% | 2 |
8 | PSORIASIFORM ERUPTION | Author keyword | 2 | 50% | 0% | 3 |
9 | TUMOR NECROSIS FACTOR ALPHA ANTAGONIST | Author keyword | 2 | 26% | 1% | 5 |
10 | ADALIMUMB | Author keyword | 1 | 100% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | NO RELAPSE | 11 | 100% | 1% | 6 |
2 | INFLIXIMAB INDUCED LUPUS | 9 | 83% | 1% | 5 |
3 | FACTOR ALPHA THERAPY | 7 | 17% | 6% | 39 |
4 | FACTOR ANTAGONIST THERAPY | 7 | 50% | 2% | 10 |
5 | NEW ONSET PSORIASIS | 6 | 71% | 1% | 5 |
6 | NEW ONSET | 6 | 19% | 5% | 29 |
7 | ANTI TNF ALPHA | 6 | 17% | 5% | 31 |
8 | ANTAGONIST THERAPY | 6 | 33% | 2% | 14 |
9 | FLEXURAL PSORIASIS | 6 | 100% | 1% | 4 |
10 | ETANERCEPT THERAPY | 5 | 17% | 4% | 28 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents | 2014 | 22 | 32 | 66% |
Demyelination and other neurological adverse events after anti-TNF therapy | 2014 | 17 | 40 | 58% |
Biologics-induced autoimmune diseases | 2013 | 34 | 41 | 49% |
Drug-induced lupus due to anti-tumor necrosis factor alpha agents | 2008 | 100 | 25 | 84% |
Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata - First 120 cases from the literature including a series of six new patients | 2008 | 126 | 29 | 59% |
Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease: A systematic literature review based on 222 cases | 2013 | 15 | 44 | 70% |
Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis | 2010 | 61 | 59 | 66% |
TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists | 2011 | 37 | 29 | 69% |
Paradoxical inflammation induced by anti-TNF agents in patients with IBD | 2012 | 38 | 82 | 39% |
Chimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety | 2015 | 2 | 127 | 19% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | AUTOIMMUNE DIS JOSEP FONT AUTOIMMUNE DIS | 1 | 33% | 0.3% | 2 |
2 | UNIT 02 UR 09 01 | 1 | 33% | 0.3% | 2 |
3 | CATTEDRA UOC REUMATOL | 1 | 50% | 0.2% | 1 |
4 | DIPARTIMENTO MED SISTEMI DERMATOL | 1 | 50% | 0.2% | 1 |
5 | EQUIPE AVENIR MALAD PRIONS CHEZ HOMME | 1 | 50% | 0.2% | 1 |
6 | FDN HOSP LA FE | 1 | 50% | 0.2% | 1 |
7 | GASTROENTEROL MED INFLAMMATORY BOWEL | 1 | 50% | 0.2% | 1 |
8 | HAMATOONKOL | 1 | 50% | 0.2% | 1 |
9 | HOSP TERR | 1 | 50% | 0.2% | 1 |
10 | MINJOZ TEACHING HOSP | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000158073 | PHARMACEUT PROTE//PRE LIGAND BINDING ASSEMBLY DOMAIN PLAD//TUMOR NECROSIS FACTOR RECEPTOR TNFR |
2 | 0.0000155997 | INFLIXIMAB//VEDOLIZUMAB//ADALIMUMAB |
3 | 0.0000145111 | PSORIASIS//EFALIZUMAB//ALEFACEPT |
4 | 0.0000133151 | ABATACEPT//TOCILIZUMAB//DISEASE MODIFYING ANTIRHEUMATIC DRUGS |
5 | 0.0000119637 | RHEUMATOID VASCULITIS//RHEUMATOID MYOSITIS//EXTRAARTICULAR MANIFESTATIONS |
6 | 0.0000103498 | PROPYLTHIOURACIL//BENZYLTHIOURACIL//DRUG INDUCED LUPUS |
7 | 0.0000078699 | IL10 GENE//INTERLEUKIN 10 PROMOTER//RHEUMATOL INTERNAL MED 3 |
8 | 0.0000071270 | ANTI TNF ALPHA THERAPIES//GENHOTEL RECH EUROPEEN POLYARTHRITE RHUMATOID//PATHOL RHEUMATOL |
9 | 0.0000062574 | BIOCHEM BIOTECH DRUGS//CEREBROVASCULAR THROMBOSIS//EXTRAINTESTINAL COMPLICATION |
10 | 0.0000061255 | IMMUNODEFICIENCY ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS//RADIATION THERAPY COMPLICATIONS//STANDARDIZED INCIDENCE RATE |